Borviz T 3.5mg Injection

Borviz T 3.5mg Injection is an anti-cancer medication. It is used in the treatment of multiple myeloma and mantle cell lymphoma. Its active ingredient is Bortezomib Injection IP which belongs to the class of proteasome inhibitor. It works by blocking the proteasome, a cellular structure responsible for breaking down damaged or unwanted proteins. The medicine does not provide a permanent cure but helps control the growth of cancer cells. It should be used consistently as prescribed by a doctor, under medical supervision to achieve the best result.

Multiple myeloma and mantle cell lymphoma

Borviz T 3.5mg Injection may cause acute and chronic side effects. Some of the symptoms may resolve on their own but some need proper medical attention to cure. Common ones include:
● High blood pressure
● Breathlessness
● Fungal infection
● Anemia
● Itching
● Pneumonia
● Dry skin
● Gastronintestinal bleeding
● Dehydration
● Motor neuropathy

Consult the doctor about proper dosage and duration of Borviz T 3.5mg Injection as it may vary depending on the medical condition. Try to take it with food to help reduce stomach upset and always follow thew doctor instructions carefully. Do not take it in the wrong way, as improper usage may reduce the effectiveness of the medication and cause serious side effects.

Borviz T 3.5mg Injection is targeted therapy. It works by blocking the proteasome, a protein which is responsible for the growth of cancer cells in the body. Proteasome inhibitor which is present in the Injection, it blocks the the cancer causing enzyme and stop the growth of tumor in the body. This helps in slowing down the disease progression and allows the body to damaged cancer cells more effectively.

• Duggett, N. A., & Flatters, S. J. (2017). Characterization of a rat model of bortezomib‐induced painful neuropathy. British journal of pharmacology, 174(24), 4812-4825.
• Yamamoto, S., Kawashiri, T., Higuchi, H., Tsutsumi, K., Ushio, S., Kaname, T., ... & Egashira, N. (2015). Behavioral and pharmacological characteristics of bortezomib-induced peripheral neuropathy in rats. Journal of pharmacological sciences, 129(1), 43-50.
• Moschetti, G., Amodeo, G., Maftei, D., Lattanzi, R., Procacci, P., Sartori, P., ... & Franchi, S. (2019). Targeting prokineticin system counteracts hypersensitivity, neuroinflammation, and tissue damage in a mouse model of bortezomib-induced peripheral neuropathy. Journal of Neuroinflammation, 16(1), 89.
• Xie, J. D., Chen, S. R., Chen, H., & Pan, H. L. (2017). Bortezomib induces neuropathic pain through protein kinase C-mediated activation of presynaptic NMDA receptors in the spinal cord. Neuropharmacology, 123, 477-487.
• Tung, D., Cheung, P. H., Kaur, P., Foreman, O., Kavirayani, A., Hain, H. S., & Saha, S. (2011). Anti-inflammatory and immunomodulatory effects of bortezomib in various in vivo models. Pharmacology, 88(1-2), 100-113.